GLP-1 drugs like Ozempic, Wegovy, and Mounjaro have been wildly successful. But as popular as they are, Americans still have very negative feelings about the people using them. In this month’s Highlight cover story, Dylan Scott explains why ‘Ozempic stigma’ hasn’t gone away, how it’s impacting GLP-1 users, and whether it could begin to fade as more and more people take the drugs. Also in this issue: How to tolerate uncertainty. What rent freezes could mean for renters. Good news about declining road deaths. And the coming AI wealth boom.
By Shayla Love
By Bryan Walsh
The one thing Ozempic still can’t fix #
By Dylan Scott
Coming August 4
How to tolerate uncertainty in a world that’s full of it #
By Elizabeth Weingarten
Coming August 5
The truth about rent control #
By Marina Bolotnikova
Coming August 5
Rise of the AI-ristocracy #
By Sara Herschander
Coming August 6
See More:
source & further reading
vox.com — original article
The US might lose the AI race to China. Should Americans care?
Can the internet survive rogue AI?
The four most important words in healthcare right now